- Home
- HOTH vs CRIS Comparison
HOTH vs CRIS Comparison
Compare HOTH & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOTH | CRIS |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 14.6M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HOTH | CRIS |
|---|---|---|
| Price | $1.04 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.50 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 150.4K | 120.9K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $0.66 | $0.96 |
| 52 Week High | $3.80 | $3.87 |
Technical Indicators
Market Signals| Indicator | HOTH | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 35.75 |
| Support Level | $0.97 | $0.96 |
| Resistance Level | $1.08 | $1.03 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 46.60 | 18.52 |
Price Performance
Historical ComparisonAbout HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.